Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity

References

• Ehrenreiter K, Kern F, Velamoor V, et al. Raf-1 addiction in Ras induced skin carcinogenesis. Cancer Cell. 2009;16:149–160. doi: 10.1016/j.ccr.2009.06.008
   PubMed Web of Science ®Google Scholar
• Karreth FA, Frese KK, DeNicola GM, et al. And Tuveson, D.A.C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 2011;1:128–136. doi: 10.1158/2159-8290.CD-10-0044
   PubMed Web of Science ®Google Scholar
• Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogenedriven non-small cell lung carcinoma. Cancer Cell. 2011;19:652–663. doi: 10.1016/j.ccr.2011.04.002
   PubMed Web of Science ®Google Scholar
• Sanclemente M, Francoz S, Esteban-Burgos L, et al. C-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism Independent of MAPK signaling. Cancer Cell. 2018;33(2):217–228. doi: 10.1016/j.ccell.2017.12.014
   PubMed Web of Science ®Google Scholar
• Blasco MT, Navas C, Martin-Serrano G, et al. Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF. Cancer Cell. 2019;35(4):573–587. doi: 10.1016/j.ccell.2019.03.002
   PubMed Web of Science ®Google Scholar
• Sanclemente M, Nieto P, Garcia-Alonso S, et al. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. Cancer Cell. 2021;39(3):294–296. doi: 10.1016/j.ccell.2021.01.008
   PubMed Web of Science ®Google Scholar
• Venkatanarayan A, Liang J, Yen I, et al. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep. 2022;38(6):110351. doi: 10.1016/j.celrep.2022.110351
   PubMed Web of Science ®Google Scholar
• Riaud M, Maxwell J, Soria-Bretones I, et al. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nat Rev Cancer. 2024;24(2):105–122. doi: 10.1038/s41568-023-00650-x
   PubMed Web of Science ®Google Scholar
• Man RJ, Zhang YL, Jiang AQ, et al. A patent review of RAF kinase inhibitors (2010-2018). Expert Opin Ther Pat. 2019;29(9):675–688. doi:10.1080/13543776.2019.1651842
   PubMed Web of Science ®Google Scholar
• Cook FA, Cook SJ. Inhibition of RAF dimers: it takes two to tango. Biochem Soc Trans. 2021;49(1):237–251. doi: 10.1042/BST20200485
   PubMed Web of Science ®Google Scholar
• Degiremenci U, Yap J, Sim YRM, et al. Drug resistance in targeted cancer therapies with RAF inhibitors. Cancer Drug Resist. 2021;4(3):665–683. doi: 10.20517/cdr.2021.36
   PubMedGoogle Scholar
• Pinzi L. On the development of B-Raf inhibitors acting through innovative mechanisms. F1000 Research. 2022;11:237. doi: 10.12688/f1000research.108761.2
   PubMedGoogle Scholar
• Vasta JD, Michaud A, Zimprich CA, et al. Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex. Cell Chem Bio. 2023;S2451-9456(23):00247–7.
   Google Scholar
• McCormick F. C-Raf in Kras mutant cancers: a moving target. Cancer Cell. 2018;33(2):158–159. doi: 10.1016/j.ccell.2018.01.017
   PubMed Web of Science ®Google Scholar
• Matallanas D, Birtwhilstle M, Romano D, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011;2(3):22–260. doi: 10.1177/1947601911407323
   Google Scholar
• Nolan AA, Aboud NK, Kolch W, et al. Hidden targets in RAF signalling pathways to block oncogenic RAS signalling. Genes (Basel). 2021;12(4):553. doi:10.3390/genes12040553
   PubMed Web of Science ®Google Scholar
• Dorard C, Madry C, Buhard O, et al. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status. Oncogene. 2023;42(20):1649–1660. doi: 10.1038/s41388-023-02683-w
   PubMed Web of Science ®Google Scholar
• Garcia-Alonso S, Mesa P, Ovejero LP, et al. Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation. Mol Cell. 2022;82(18):3438–3452. doi: 10.1016/j.molcel.2022.08.012
   PubMed Web of Science ®Google Scholar
• Lu H, Zhou Q, He J, et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020;5(1):213. doi: 10.1038/s41392-020-00315-3
   PubMed Web of Science ®Google Scholar
• Sorolla A, Wang E, Golden E, et al. Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene. 2020;39(6):1167–1184. doi: 10.1038/s41388-019-1056-3
   PubMed Web of Science ®Google Scholar
• An S, Yang Y, Ward R, et al. Raf-interactome in tuning the complexity and diversity of raf function. FEBS J. 2014;282(1):32–53. doi: 10.1111/febs.13113
   PubMed Web of Science ®Google Scholar
• Iglesias-Martinez LF, Rauch N, Wynne K, et al. Interactome dynamics of RAF1-BRAF kinase monomers and dimers. Sci Data. 2023;10(1):203. doi: 10.1038/s41597-023-02115-0
   PubMed Web of Science ®Google Scholar
• Kato-Stankiewicz J, Hakimi I, Zhi G, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. PNAS. 2002;99(22):14398–14403. doi: 10.1073/pnas.222222699
   PubMed Web of Science ®Google Scholar
• González-Pérez V, Reiner DJ, Alan JK, et al. Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J Mol Signal. 2010;5(2):2. doi: 10.1186/1750-2187-5-2
   PubMedGoogle Scholar
• Gunderwala AY, Nimbvikar AA, Cope NJ, et al. Development of allosteric BRAF peptide inhibitors targeting the dimer interface of BRAF. ACS Chem Biol. 2019;14(7):1471–1480. doi: 10.1021/acschembio.9b00191
   PubMed Web of Science ®Google Scholar
• Brown KM, Day JP, Huston E, et al. Phosphodiesterase-8A binds to and regulates raf-1 kinase. Proc Nat Acad Sci. 2013;110(16):E1533–E1542. doi: 10.1073/pnas.1303004110
   PubMed Web of Science ®Google Scholar
• Blair CM, Walsh NM, Littman BH, et al. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disruptors of PDE8A - C-Raf. BMC Cancer. 2019;19(1):266. doi: 10.1186/s12885-019-5489-4
   PubMedGoogle Scholar
• Basole CP, Nguyen RK, Lamothe K, et al. PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling complex. Cell Signal. 2017;40:62–72. doi: 10.1016/j.cellsig.2017.08.007
   PubMed Web of Science ®Google Scholar
• Kenanova DN, Visser EJ, Virta JM, et al. A systemic approach to discovery of protein-protein interaction stabilizers. ACS Cent Sci. 2023;9(5):937–946. doi: 10.1021/acscentsci.2c01449
   PubMed Web of Science ®Google Scholar
• Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Cancer Res. 2020;80(14):2969–2974. doi: 10.1158/0008-5472.CAN-19-3682
   PubMed Web of Science ®Google Scholar
• Sealover NE, Kortum RL. Heterogeneity in RAS mutations: One size does not fit all. Sci Signal. 2022;15(746):eadc9816. doi: 10.1126/scisignal.adc9816
   PubMed Web of Science ®Google Scholar